Fig. 3: ApoE peptide enabled the brain targeting delivery of Nano-reshaper.
From: Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
a Scheme to illustrate DiI-labeled CaP nanoparticles crossing BBB model constructed by bEnd.3 cells. b The transport ratio (%) of DiI-labeled pLIGHT@CaCP and Nano-reshaper following 4 h incubation in vitro model. Blockade experiment was performed by pretreating bEnd.3 cells with free ApoE peptide (100 μg/mL) for 1 h before Nano-reshaper incubation (n = 3 samples per group). c Ex vivo DiR fluorescence imaging of excised brains obtained from healthy mice killed at 24 h post-injection. d Semi-quantitative results of the ex vivo brain radiant efficiency shown in c (n = 3 mice). e Real-time whole-body DiR fluorescence imaging of mice bearing intracranial GL261 GBM after i.v. injection of DiR-labeled pLIGHT@CaCP and Nano-reshaper. f Semi-quantitative results of the in vivo brain radiant efficiency (n = 3 mice). g Ex vivo DiR fluorescence imaging of excised brains obtained from mice bearing intracranial GL261 GBM killed at 24 h post-injection. h Semi-quantitative results of the ex vivo brain radiant efficiency shown in g (n = 3 mice). Data were shown as mean ± SD. Error bars represent SD. Significant difference was evaluated in b, d, f, and h using two-tailed unpaired Student’s t test. Source data are provided as a Source Data file.
